 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
18 January 2000 | Volume 132 Issue 2 | Pages 134-143
Two forms of cyclooxygenase, cyclooxygenase-1 (COX-1) and cyclooxygenase 2 (COX-2), act as rate-limiting enzymes in prostaglandin and thromboxane synthesis. Discovery of these compounds led to the development of drugs that selectively or specifically inhibit the COX-2 isoform. Although the COX-1 isoform is expressed at fairly constant levels in cells, including the gastrointestinal mucosa and platelets, expression of COX-2 varies greatly. In many cells, low expression of COX-2 can be upregulated by various stimuli, including inflammatory cytokines, bacterial toxins, and growth factors; this suggests that COX-2 plays a role in inflammation, infection, and cellular proliferation.
It was thought that newly developed drugs designed to block COX-2 but not COX-1 would have anti-inflammatory properties and would avoid inhibiting the synthesis of gastrointestinal prostaglandins (thereby avoiding ulcers) and platelet thromboxane (thereby avoiding bleeding). Gastrointestinal ulcers and bleeding are side effects of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) that block COX-1 and COX-2. Meloxicam and nimesulide, selective COX-2 inhibitors available outside the United States, are as effective as traditional NSAIDs but have similar gastrointestinal side effects. Celecoxib (Celebrex, G.D. Searle and Co., Chicago, Illinois) and rofecoxib (Vioxx, Merck and Co., Inc., West Point, Pennsylvania), selective COX-2 inhibitors approved in the United States in the past year, are also as effective as traditional NSAIDs. However, celecoxib and rofecoxib have no antiplatelet activity and lead to fewer endoscopically detected gastric and duodenal ulcers than traditional NSAIDs, such as ibuprofen or naproxen.
Preliminary analyses of data pooled from several trials suggest that celecoxib and rofecoxib are associated with fewer clinically symptomatic ulcers and ulcer complications than traditional NSAIDs are. Postmarketing surveillance should help clarify the actual risk for serious ulcer complications with these new COX-2 inhibitors and reveal other potential nongastrointestinal toxic reactions that can result from their use.
Author and Article Information
From University of Texas Southwestern Medical Center, Dallas, Texas; and Salix Pharmaceuticals, Inc., Palo Alto, California.
Note added in proof: The equal efficacy of celecoxib and naproxen in rheumatoid arthritis, with fewer endoscopic ulcers in the celecoxib groups, was reported in a recent paper (Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal efects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999; 282:1921-8).
Disclaimer: Dr. Feldman performed clinical studies of rofecoxib for Merck and Co., Inc., before the drug received FDA approval. He currently has no consulting or financial arrangements with any company that manufactures NSAIDs or COX-1-COX-2 inhibitors. Mr. McMahon and Salix Pharmaceuticals, Inc., have no current financial interest in the use of NSAIDs or COX-1-COX-2 inhibitors for the treatment of arthritis or other conditions and are not now involved in the manufacture of any related drugs or products.
Acknowledgments: The authors thank Drs. Byron Cryer, Ping Hsu, Lorin Johnson, and Salahuddin Kazi for their useful comments and Vicky Robertson for helping prepare the manuscript.
Grant Support: By the Veterans' Administration (Merit Award to Dr. Feldman).
Requests for Reprints: Mark Feldman, MD, Medical Service (111), Dallas Veterans Affairs Medical Center, 4500 South Lancaster Road, Dallas, TX 75216; e-mail, mark.feldman{at}med.va.gov. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. Feldman: Medical Service (111), Dallas Veterans Affairs Medical Center, 4500 South Lancaster Road, Dallas, TX 75216.
Mr. McMahon: Oncology Therapeutics Network, 345 Oyster Point Boulevard, Suite 405, South San Francisco, CA 94080. REVIEW
Do Cyclooxygenase-2 Inhibitors Provide Benefits Similar to Those of Traditional Nonsteroidal Anti-Inflammatory Drugs, with Less Gastrointestinal Toxicity?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  L. Vogt, D. de Zeeuw, A. J. J. Woittiez, and G. Navis Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients Nephrol. Dial. Transplant., November 26, 2008; (2008) gfn644v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Iadecola and P. B. Gorelick The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets Stroke, February 1, 2005; 36(2): 182 - 185. [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Sinicrope, E. Half, J. S. Morris, P. M. Lynch, J. D. Morrow, B. Levin, E. T. Hawk, D. S. Cohen, G. D. Ayers, and L. C. Stephens Cell Proliferation and Apoptotic Indices Predict Adenoma Regression in a Placebo-Controlled Trial of Celecoxib in Familial Adenomatous Polyposis Patients Cancer Epidemiol. Biomarkers Prev., June 1, 2004; 13(6): 920 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Smith and W. Baird Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population American Journal of Hospice and Palliative Medicine, July 1, 2003; 20(4): 297 - 306. [Abstract] [PDF]
|
|
|
|
 |
|
 J. P. Case, A. J. Baliunas, and J. A. Block Lack of Efficacy of Acetaminophen in Treating Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo-Controlled Comparison Trial With Diclofenac Sodium Arch Intern Med, January 27, 2003; 163(2): 169 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G Fam Treating acute gouty arthritis with selective COX 2 inhibitors BMJ, November 2, 2002; 325(7371): 980 - 981. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sun, X. M. Tang, E. Half, M. T. Kuo, and F. A. Sinicrope Cyclooxygenase-2 Overexpression Reduces Apoptotic Susceptibility by Inhibiting the Cytochrome c-dependent Apoptotic Pathway in Human Colon Cancer Cells Cancer Res., November 1, 2002; 62(21): 6323 - 6328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mamdani, P. A Rochon, D. N Juurlink, A. Kopp, G. M Anderson, G. Naglie, P. C Austin, and A. Laupacis Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs BMJ, September 21, 2002; 325(7365): 624 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Mastbergen, F. P. J. G. Lafeber, and J. W. J. Bijlsma Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage Rheumatology, July 1, 2002; 41(7): 801 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sample, M. Wargovich, S. M. Fischer, N. Inamdar, P. Schwartz, X. Wang, K.-A. Do, F. A. Sinicrope, N. E. Day, D. E. G. Shuker, et al. A Dose-finding Study of Aspirin for Chemoprevention Utilizing Rectal Mucosal Prostaglandin E2 Levels as a Biomarker Cancer Epidemiol. Biomarkers Prev., March 1, 2002; 11(3): 275 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. FitzGerald and C. Patrono The Coxibs, Selective Inhibitors of Cyclooxygenase-2 N. Engl. J. Med., August 9, 2001; 345(6): 433 - 442. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. MOORE and E. V. HERSH Celecoxib and rofecoxib: The role of COX-2 inhibitors in dental practice J Am Dent Assoc, April 1, 2001; 132(4): 451 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Ostensen and P M Villiger Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus Lupus, March 1, 2001; 10(3): 135 - 139. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Feldman, K. Shewmake, and B. Cryer Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans Am J Physiol Gastrointest Liver Physiol, November 1, 2000; 279(5): G1113 - G1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Lichtenstein and M. M. Wolfe COX-2-Selective NSAIDs: New and Improved? JAMA, September 13, 2000; 284(10): 1297 - 1299. [Full Text] [PDF]
|
|
Article
